Methods of treating fibrosis

Patent metadata

Field	Value
Publication number	US-12291494-B2
Application number	US-202318355790-A
Country	US
Kind code	B2
Filing date	Jul 20, 2023
Priority date	Feb 9, 2012
Publication date	May 6, 2025
Grant date	May 6, 2025

Abstract

The present disclosure is directed in part to methods of treating fibrosis, e.g., hepatic fibrosis and/or intestinal fibrosis, comprising administering to a patient in need thereof an effective amount of a disclosed compound.

First claim

We claim:

1. A method of treating alpha 1-antitrypsin deficiency in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound, wherein the compound is 2-methoxy-3-(4′-aminophenyl) propionic acid, represented by the formula:

or a pharmaceutically acceptable salt or a stereoisomer thereof.

2. The method of claim 1 , wherein the compound is (S)-2-methoxy-3-(4′-aminophenyl) propionic acid, or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein the compound is (R)-2-methoxy-3-(4′-aminophenyl) propionic acid, or a pharmaceutically acceptable salt thereof.

4. A method of treating alpha 1-antitrypsin deficiency in a subject in need thereof, comprising administering to the subject a pharmaceutical preparation comprising a therapeutically effective amount of 2-methoxy-3-(4′-aminophenyl) propionic acid (compound 34), or a pharmaceutically acceptable salt or a stereoisomer thereof, and one or more pharmaceutically acceptable carriers.

5. The method of claim 4 , wherein the pharmaceutical preparation comprises a therapeutically effective amount of (S)-2-methoxy-3-(4′-aminophenyl) propionic acid, or a pharmaceutically acceptable salt thereof.

6. The method of claim 4 , wherein the pharmaceutical preparation comprises a therapeutically effective amount of (R)-2-methoxy-3-(4′-aminophenyl) propionic acid, or a pharmaceutically acceptable salt thereof.

7. The method of claim 4 , wherein the pharmaceutical preparation is for oral administration.

8. The method of claim 4 , wherein the subject is human.

9. The method of claim 4 , wherein the subject is currently suffering or has suffered from hepatitis B or hepatitis C, or wherein the subject has cirrhosis.

Assignees

• Nogra Pharma Ltd

Inventors

• Baroni Sergio
• Bellinvia Salvatore
• Viti Francesca

Classifications

• A61P1/04

  for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title

• A61K31/357

  having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel · CPC title

• A61K31/343

  condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone · CPC title

• A61K31/196 Primary

  the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil · CPC title

• C07C229/44 Primary

  with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by unsaturated carbon chains · CPC title